TRDA earnings: real EPS beat/miss history, analyst consensus Buy, P/E -1.54. Updated 2026-07-23.
Entrada Therapeutics (TRDA) Research Hub
Entrada Therapeutics (TRDA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 6.8 USD (-4.36%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.54, market cap 0.24B. This hub links to the full technical, earnings and options research available for TRDA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.8 USD (-4.36%) |
| 52-week range | 5.72 USD – 8.1 USD |
| Trend regime | Range |
| 14-day RSI | 49 (Neutral) |
| Trailing P/E | -1.54 |
| Market cap | 0.24B |
| Dividend yield | 0.00% |
Available research for TRDA
Covered Call on TRDA: how it works, illustrative setup around the real 6.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TRDA: how it works, illustrative setup around the real 6.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TRDA: how it works, illustrative setup around the real 6.8 USD price, max profit/loss, breakeven and when to use it. Educational.
TRDA technical analysis: range, last 6.8 USD, RSI 49, 52w range 5.72 USD–8.1 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TRDA in?
Entrada Therapeutics (TRDA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TRDA in an uptrend or downtrend?
As of 2026-09-11, TRDA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TRDA's trailing P/E ratio?
TRDA's trailing P/E is -1.54, with a market cap of 0.24B. See the earnings research page for full valuation detail.